Home » Ipilimumab Study Shows Clinical Activity in Advanced NSCLC
Ipilimumab Study Shows Clinical Activity in Advanced NSCLC
Bristol-Myers Squibb announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer (NSCLC).
MarketWatch
MarketWatch
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May